November 18, 10:24 AM
SMBC Nikko analyst David Dai initiates coverage on Nkarta (NASDAQ:NKTX) with a Outperform rating and announces Price Target of $50.
MaxCyte Reports Strategic Platform License With Nkarta to Advance Natural Killer Cell Therapy Programs
October 28, 10:01 AM
MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT, MXCN)), a leading provider of enabling platform technologies for ex-vivo cell engineering, today announces the signing of a strategic platform license (SPL) with Nkarta, Inc., a
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
October 8, 7:31 AM
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7)
September 7, 4:58 AM
Gainers Innate Pharma S.A. (NASDAQ: IPHA) shares surged 47.1% to settle at $6.15 on Friday after SVB Leerink upgraded the stock from Market Perform to Outperform.
August 12, 5:28 PM